Back to Agenda
Master Protocols: New Approaches to Enrolling Hard-to-Find Subjects and Expediting Drug Development
Session Chair(s)
Theresa Crofts Ashton, PHD
Senior Director, Clinical Statistics, GlaxoSmithKline, United States
Master ("umbrella") protocols that have multiple treatment options are being used to optimize enrollment and expedite drug development based on biomarkers/specific disease traits. This session will discuss this approach and the benefits and challenges of these multi-company collaborations.
Learning Objective : Describe the Umbrella concept; Discuss key considerations.
Speaker(s)
The Use of Statistical Innovation to Increase Efficiency in Difficult-to-Enroll Clinical Trials
Director of Research. Senior Statistical Scientist, Berry Consultants, United States
Combined Adaptive Early Phase Trials: From First-Time-in-Human to Proof of Concept in One Protocol
Medical Director, Richmond Pharmacology Ltd., United Kingdom
Beat AML: Practicalities and Lessons Learned From the Construct of a 10-Study Leukemia Umbrella Trial
Chief Scientific Officer, Eilean Therapeutics, United States
Panelist
Chief Scientific Officer , Syneos Health, United States
Have an account?